Positive Outlook for TransMedics Group: Buy Rating Justified by Aviation and Transplant Data Trends
I'm PortAI, I can summarize articles.
Canaccord Genuity analyst William Plovanic maintains a Buy rating for TransMedics Group, citing positive aviation and transplant data trends. The aviation data suggests recovery in flights, while UNOS data shows strong organ transplant trends, supporting revenue expectations. Another report also reiterates a Buy rating with a $155 target. TMDX's price dropped 3.3% over six months.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments